


Supplementary information

**Advances in the identification and validation of
autism biomarkers**

In the format provided by the authors



Supplementary Figure 1 | AIMS-2-TRIALS biomarker discovery cohort and preclinical workstreams, with the key showing the mapping between study design and proposed context of use of candidate biomarkers in the development pipeline. Utility as pharmacodynamic/response and predictive markers is assessed in complementary pharmaco-challenge proof-of-concept studies and innovative clinical trial designs. LEAP, Longitudinal European Autism Project; SynaG, Synaptic Gene Study; PASS, Prenatal Alcohol in SIDS and Stillbirth Network (leading the Safe Passage Study).



Supplementary Figure 2 | Pipeline for identifying/ validating candidate biomarkers for specific context(s) of use, across data modality. SOP, standard operating procedures; DV, dependent variables; CoU, context of use.